Skip to main content
. 2025 Jul 25;21(11):4834–4850. doi: 10.7150/ijbs.105629

Figure 7.

Figure 7

Lnc-CRAT40 is upregulated in CRC via METTL3-mediated m6A modification. A. Predicted m6A modification sites within lnc-CRAT40 transcript (SRAMP database). B. The decrease of lnc-CRAT40 expression in HCT15 and SW480 cells treated with methylation inhibitor 3-DAA for 24 h (qRT-PCR). C. Quantitative analysis of METTL3 expression in 49 paired CRC and adjacent normal tissues by qRT-PCR. D. Elevated METTL3 expression in CRC tissues (TCGA dataset). E. Correlation between lnc-CRAT40 and METTL3 expression in CRC tissue (n=49). F. Positive correlation between lnc-CRAT40 and METTL3 expression in CRC (GEPIA 2). G. Kaplan-Meier analysis showing worse disease-free survival in CRC patients with high METTL3 expression. H. Western blot confirming METTL3 knockdown efficiency in CRC cells. I. qRT-PCR showing reduced METTL3 and lnc-CRAT40 expression upon METTL3 knockdown. J. MeRIP-qPCR demonstrating decreased m6A modification on lnc-CRAT40 following METTL3 knockdown. K, L. RNA stability assay showing shortened half-life of lnc-CRAT40 transcript after METTL3 knockdown. Data are mean ± SD of three independent experiments. *P < 0.1, **P < 0.01, ***P < 0.001, ****P < 0.0001.